文献速递白血病造血干细胞移植与细胞治疗

利用微小残留病评估重新定义儿童急性淋巴细胞白血病的诱导失败

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2017-01-03

该研究基于UKALL2003多中心随机试验中3113例儿童急性淋巴细胞白血病患者,评估诱导结束时微小残留病(MRD)在识别和分层诱导失败中的作用。将形态学诱导失败和/或MRD≥5%重新定义诱导失败,可识别3.9%的试验队列,其5年无事件生存率为48.0%。在B-other ALL中约三分之一存在PDGFRB基因融合,尤其是EBF1-PDGFRB,提示遗传筛查的重要性。

要点

  • 形态学诱导失败患者5年无事件生存率为50.7%,5年总生存率为57.7%。
  • 形态学缓解但MRD≥5%的患者5年无事件生存率为47.0%,与形态学诱导失败相似。
  • 重新定义诱导失败(形态学失败和/或MRD≥5%)识别3.9%患者,5年无事件生存率48.0%。

核心结论

  • 将诱导结束时MRD水平与形态学结合,比单纯形态学更精确地识别诱导失败。
  • 该组中EBF1-PDGFRB融合的高发生率强调遗传筛查对识别潜在靶向异常的重要性。

研究设计与样本

  • 研究纳入2003年至2011年间在医学研究理事会UKALL2003多中心随机试验(NCT00222612)中治疗的3113例患者。
  • MRD通过标准化实时定量PCR检测,中位随访时间为5年9个月。

主要发现

  • 59例(1.9%)患者存在形态学诱导失败,5年无事件生存率为50.7%(95%CI,37.4至64.0),5年总生存率为57.7%(95%CI,44.2至71.2)。
  • 在形态学诱导失败患者中,M2骨髓且诱导结束时MRD水平低(<0.01%)的6/44例患者5年无事件生存率为100%。
  • 在形态学缓解患者中,2.3%(61/2633)存在高MRD(≥5%),5年无事件生存率为47.0%(95%CI,32.9至61.1),与形态学诱导失败相似。
  • 重新定义诱导失败包括形态学诱导失败和/或MRD≥5%,识别了试验队列中3.9%(120/3133)的患者,5年无事件生存率为48.0%(95%CI,39.3至58.6)。
  • 诱导失败(形态学或MRD≥5%)最常见于T-ALL(10.1%;39/386例T-ALL)和B-other ALL(5.6%;43/772例B-other),B-other组遗传检测显示近三分之一存在PDGFRB基因融合,尤其是EBF1-PDGFRB。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) assessment in the identification and stratification of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) and to identify genetic abnormalities that drive disease in these patients. Patients and Methods Analysis included 3,113 patients who were treated in the Medical Research Council UKALL2003 multicenter randomized trial (NCT00222612) between 2003 and 2011. MRD was measured by using standardized real-time quantitative PCR. Median follow-up was 5 years 9 months. Results Fifty-nine patients (1.9%) had morphologic induction failure with 5-year event-free survival (EFS) of 50.7% (95% CI, 37.4 to 64.0) and 5-year overall survival of 57.7% (95% CI, 44.2 to 71.2). Of these, a small proportion of patients with M2 marrow (6 of 44) and a low EOI MRD level (< 0.01%) had 5-year EFS of 100%. Conversely, among patients with morphologic remission 2.3% (61 of 2,633) had high MRD (≥ 5%) and 5-year EFS of 47.0% (95% CI, 32.9 to 61.1), which was similar to those with morphologic induction failure. Redefining induction failure to include morphologic induction failure and/or MRD ≥ 5% identified 3.9% (120 of 3,133 patients) of the trial cohort with 5-year EFS of 48.0% (95% CI, 39.3 to 58.6). Induction failure (morphologic or MRD ≥ 5%) occurred most frequently in T-ALL (10.1%; 39 of 386 T-ALL cases) and B-other ALL, that is, lacking established chromosomal abnormalities (5.6%; 43 of 772 B-other cases). Genetic testing within the B-other group revealed the presence of PDGFRB gene fusions, particularly EBF1-PDGFRB, in almost one third of B-other ALL cases. Conclusion Integration of EOI MRD level with morphology identifies induction failure more precisely than morphology alone. Prevalence of EBF1-PDGFRB fusions in this group highlights the importance of genetic screening to identify abnormalities that may be targets for novel agents.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. O'Connor D, Moorman AV, Wade R, et al. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2017. PMID: 28045622. doi:10.1200/JCO.2016.69.6278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。